Biofrontera AG provided earnings guidance for the year 2022. The Management Board stated therein that with the expectation of a further recovery of the most important sales markets from the pandemic consequences, the company should achieve sales between EUR 24 and 27 million for the 2022 financial year following the realignment of the company through the independence of Biofrontera Inc. and deconsolidation. The company is expected to achieve approximately break-even EBITDA and a negative EBIT in the low single-digit million range in 2022.